Skip to main content
. 2020 Jan 2;69(3):365–372. doi: 10.1007/s00262-019-02452-3

Fig. 2.

Fig. 2

Kaplan–Meier estimates of overall survival (a) and progression-free survival (b) comparing chemotherapy alone and chemotherapy combined with immune checkpoint inhibitors (ICIs). mOS median overall survival, HR hazard ratio, ICI + chemo the group of patients receiving immune checkpoint inhibitors and chemotherapy, Chemo the group of patients receiving chemotherapy